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Purpose. In this study, we tested the hypothesis that rosiglitazone (RSG) with insulin is able to quench oxidative stress initiated by
high glucose through prevention of NAD(P)H oxidase activation. Methods and Materials. Male albino Wistar rats were randomly
divided into an untreated control group (C), a diabetic group (D) that was treated with a single intraperitoneal injection of
streptozotocin (45 mgkg−1), and rosiglitazone group that was treated with RSG twice daily by gavage and insulin once daily by
subcutaneous injection (group B). HbA1c and blood glucose levels in the circulation and malondialdehyde and 3-nitrotyrosine
levels in left ventricular muscle were measured. Result. Treatment of D rats with group B resulted in a time-dependent decrease
in blood glucose. We found that the lipid profile and HbA1c levels in group B reached the control group D rat values at the end
of the treatment period. There was an increase in 3-nitrotyrosine levels in group D compared to group C. Malondialdehyde and
3-nitrotyrosine levels were found to be decreased in group B compared to group D (P < 0.05). Conclusion. Our data suggests that
the treatment of diabetic rats with group B for 8 weeks may decrease the oxidative/nitrosative stress in left ventricular tissue of rats.
Thus, in diabetes-related vascular diseases, group B treatment may be cardioprotective.
1. Introduction
Hyperglycemia induces protein glycation, systemic low
grade inflammation, and endothelial dysfunction [1]. As a
consequence, diabetes is one of the main risk factor for
cardiovascular disease. Hyperglycemia-induced endothelial
dysfunction is characterized by an enhanced production
of reactive oxygen species (ROS), which are important
actors in the development of vascular damage. Consistently,
antioxidant agents are able to rescue hyperglycemia-induced
vascular dysfunction [1, 2].
Insulin resistance is a fundamental abnormality in the
pathogenesis of type-2 diabetes. A number of different mech-
anisms have been proposed to explain the mechanism of
insulin resistance. Recent information suggests that a com-
mon feature of the development of insulin resistance is an
increased production of ROS and that reduction in ROS
production results in improved insulin sensitivity [3].
Rosiglitazone, a member of the thiazolidinediones (TZD)
class of antidiabetic agents, is an agonist of the nuclear hor-
mone receptor peroxisome proliferator gamma (PPARγ). Ex-
pression of these receptors is most abundant in adipose tissue
where they play a central role in adipogenesis and lipid meta-
bolism [4].
Thiazolidinediones (TZD) are used clinically in diabetic
patients by virtue of their insulin-sensitizing action, con-
veyed by the activation of the nuclear transcription factor
PPARγ [5]. In addition, these agents have remarkable pleio-
tropic activities: by improving endothelial function and
systemic inflammation, they are expected to exert direct ben-
eficial effects on cardiovascular risk, which are not mediated
by the improvement in glucose metabolism. In this regard,
pioglitazone was shown to abolish ROS production in 3T3-
L1 adipocytes [6], whereas RSG reduced NADPH-stimulated
superoxide production in aortas from diabetic mice [7], and
2 Experimental Diabetes Research
troglitazone diminished ROS generation in leukocytes from
obese subjects [8]. However, the molecular mechanism by
which TZDs attenuate oxidative stress is not clear.
PPAR-γ activation reduced O2− generation and NADPH
oxidase expression in vascular endothelial cells in vitro and
increased NO production through PPARγ-dependent mech-
anisms [9].
In this study, treatment of insulin and rosiglitazone may
decrease oxidative stress in diabetic rats, which may be car-
dioprotective in setting diabetic vascular disease, Therefore,
the aim of the present study was to dissect the molecu-
lar mechanisms underlying the effects of RSG on hyper-
glycemia-induced ROS production.
2. Material and Method
2.1. Animal Handling and Treatment Protocol. Twenty-four
healthy male Wistar albino male rats (250–320 g) were
selected for the study. All animal procedures were performed
according to the Guide for the Care and Use of Laboratory
Animals of the US National Institutes of Health and approval
of the ethics committee of our institution was obtained
before the commencement of the study. The diabetic rat
model used in our experiments was based on partial damage
of pancreatic beta-cells resulting from a single administra-
tion of streptozotocin (45 mg/kg, STZ, Sigma Chemical Co.,
USA) intravenously (dissolved in 0.01 M sodium citrate, pH
adjusted to 4.5). This model of experimental diabetes is
associated with partial deficits in insulin secretion and con-
sequential hyperglycaemia, without changes in peripheral
insulin resistance [10]. STZ-injected animals were accepted
as diabetic if blood glucose levels were more than 200 mg/dL
[11, 12] using a glucometer (Aquo-Check, Roche) after a
one-week period and at least three high blood glucose levels.
We used three groups randomly constituted four groups:
(1) Nondiabetic control animals (C): rats orally fed with
standard rat nutrients and water, and (2) diabetic group (D),
and (3) rosiglitazone with insulin group (B) treated diabetic
animals group (B) rats treated with 4 mg/kg/day RSG two
times a day by gavage and Insulin Treatment Protocols
eight weeks after the initial STZ injections, diabetic animals
were randomly divided into one group. One group of these
animals was placed on an insulin regimen (NPH Ilentin
II, intermediate acting) for 8 weeks. Insulin doses were
individually adjusted so as to maintain euglycemic states and
varied between 1 uU/kg (s.c.), given once per day between
9:00 AM. Animals were fed with standard rat nutrient
and water without restriction throughout the experiment.
Rosiglitazone-treated groups were given group B for 8 weeks
and blood glucose levels as well as body weights were
measured once weekly.
2.1.1. Isolation of Left Ventricular Muscles. Wistar albino rats
were anesthetized with dietyl ether. Hearts were rapidly
removed and the left ventricular muscles were dissected.
The muscle was mounted in a Petri cup (about 2 mL
volume) and perfused continuously (6–8 mL min−1) with
oxygenated (95% O2 and 5% CO2) krebs buffer, (con-
stituents in mmol L−1: 113 NaCl, 4.7 KCL, 1.2 MgSO4·7H2O,
1.9 CaCl2·2H2O, 1.2 KH2PO4, 25 NaHCO3 11.5 glucose, pH
7,4) solution at a constant flow rate.
2.2. Biochemical Analysis
2.2.1. Measurements of HbA1c and Lipid Parameters. Blood
plasma HbA1c was determined immunoturbidimetrically
(Pfeiffer M). Triacylglycerol (TAG), total cholesterol (TC),
and high-density lipoprotein-cholesterol (HDL-C) were
analyzed by glycerophosphate oxidase, peroxidase/4-amino-
phenazone (GPO/PAP), cholesterol oxidase, peroxidase/4-
aminophenazone (CHOD/PAP), and direct COHD/PAP
enzymatic colorimetric methods, respectively. The very low
density lipoprotein-cholesterol (VLDL-C) and low density
lipoprotein-cholesterol (LDL-C) was calculated according to
the equation described by Friedewald et al. [13]. All these
parameters were determined by Cobas Integra 800 bio-
chemical analyzer (Roche Diagnostics, GmbH, Mannheim,
Germany).
2.2.2. Measurement of Malondialdehyde. A tissue specimen
of 50 mg was homogenized in 0.15 mol/L KCL. After the
homogenate had been centrifuged at 1600 rpm, the MDA
levels in tissue homogenate supernatant were determined
by the thiobarbituric acid (TBA) reaction according to Yagi
[14]. The principle of the method is based on measuring
absorbance of the pink color produced by the interaction
of TBA with MDA at 530 nm. Values were expressed as
nmol/mL.
2.2.3. Measurement of 3-Nitroyrosine. 3-NT and tyro-
sine were obtained from Sigma Chemical (St. Louis,
USA). H2O2, sodium acetate, citrate, NaOH, HCL, H3PO4,
KH2PO4, and K2HPO4 were purchased from Merck Chemi-
cal (Deisenhofen, Germany). All organic solvents were HPLC
grade. The tissues were homogenized in ice-cold phosphate-
buffered saline (pH 7.4). Equivalent amounts of each sample
were hydrolyzed in 6 N HCI at 100◦C for 18–24 h, and
then samples were analyzed on an Agilent 1100 series
HPLC apparatus (Germany). The analytical column was a
5 μm pore size Spherisorb ODS-2 C18 reverse-phase column
(4.6 × 250 mm; HICHROM, Waters Spherisorb, UK). The
guard column was a C18 cartridge (HICHROM, Waters
Spherisorb, UK). The mobile phase was 50 mmol/L sodium
acetate/50 mmol/L citrate/8% (v/v) methanol, and pH 3.1.
HPLC analysis was performed under isocratic conditions at
a flow rate of 1 mL min−1 and UV detector set at 274 nm. 3-
NT and tyrosine peaks were determined according to their
retention times and the peaks were confirmed by spiking
with added exogenous 3-NT [15] and tyrosine (10 μmol/L).
3-NT levels were expressed as 3-NT/total tyrosine.
2.3. Statistical Analysis. The results were expressed as mean
± standard deviation (SD). Kruskal-Wallis (which is non-
parametric) test was used for the comparison of groups.
When significant differences were observed (P < 0.05),
Tukey multiple comparison test was used to determine
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Figure 1: The effects of rosiglitazone with insulin combine on lipid
prolifies. C: control rats, D: diabetic rat, group B: rosiglitazone with
insulin-treated diabetic rats. Data are expressed as mean + SEM.
∗P < 0.001 in D compared with group B, C. TAG: triacylglycerol,
TC: total cholesterol, HDL-C: high-density lipoprotein-cholesterol
VLDL-C; very low-density lipoprotein-cholesterol, LDL-C; low-
density lipoprotein-cholesterol.
the difference between groups. Statistical analyses were car-
ried out using the SPSS statistical software package (SPSS for
Windows version 13.0, SPSS Inc., Chicago, Illinois, USA).
3. Results
3.1. Effects of Rosiglitazone with Insulin Combination on
HbA1c and Lipid Profiles Tolerance in Control and Diabetic
Rats. TAG: triacylglycerol, TC: total cholesterol, HDL-C:
high-density lipoprotein-cholesterol, VLDL-C: very low-
density lipoprotein-cholesterol, LDL-C: low-density lip-
oprotein-cholesterol levels of study groups are shown in
Figures 1 and 2. Group B had significant effects on HbA1c
and lipid profiles in diabetic rats (P < 0.05). HbA1c and TC,
TAG and VLDL levels were significantly increased in diabetic
group compared with C group (P < 0.05). LDL-C levels were
not significantly different between groups (Figures 1 and 2).
3.2. Effects of Rosiglitazone with Insulin Combination on Blood
Glucose in Control and Diabetic Rats. Treatment of D rats
with group B resulted in a time-dependent decrease in
blood glucose levels. The reduction in blood glucose became
significant by week 2 of treatment compared to the diabetic
groups (P < 0.05) (Table 1). At the end of the study period,
the diabetic group had lower body weights than the control
group (P < 0.05). Treatment of diabetic rats with group
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Figure 2: The effects of rosiglitazone with insulin combine on
HbA1c. C: control rats, D: diabetic rat, group B: rosiglitazone with
insulin-treated diabetic rats. Data are expressed as mean + SEM.
∗P < 0.001 in D compared with groups B and C. HbA1c: hemo-
globin A1c.
B for 8 weeks showed a significant increase (27.3%) in the
body weight compared to the diabetic group (P < 0.05). On
the other hand, D rats for 8 weeks resulted in a significant
decrease (39.9%) in the body weight compared to the control
group (P < 0.05) (Table 2).
3.3. Effects of Rosiglitazone with Insulin Combination Therapy
on Malondialdehyde Levels in Control and Diabetic Rats.
Treatment of diabetic rats with RSG (4 mg/kg/day) for 8
weeks brought about a significant decrease at MDA levels
compared with the C groups (P < 0.001). MDA levels in
D + RSG group were not significantly compared with the
B groups. In the diabetic group, MDA levels were found to
be increased compared with the C (P < 0.04), D + RSG,
D + INS, group B (P < 0.001) groups and the differences
between these groups were significant. MDA levels were not
statistically significant between the C and B groups. MDA
levels in the C group were significantly different compared
to the group B (P < 0.003) (Figure 3).
3.4. Effects of Rosiglitazone with Insulin Combination Therapy
on 3-Nitroyrosine Levels in Control and Diabetic Rats. 3-
NT levels in the C group were not significantly different
compared to the D + RSG and D + INS groups. In diabetic
group, 3-NT levels were found to be increased when com-
pared with C and B groups and the differences between these
groups were significant, respectively (P < 0.005). There were
no statistically significant differences between the B groups.
Treatment of diabetic rats with group B (4 mg/kg/day and
1 uU/kg−1) for 8 weeks brought about a significant decrease
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Table 1: Blood glucose levels in the study groups.
Weeks
Groups 0 1 2 3 4 5 6 7 8
C (mg/dL) 99.1± 1.1 101.2± 1.9 102.0± 1.7 99.6± 1.7 99.1± 1.2 98.8± 1.7 99.4± 1.4 101.1± 2.7 100.7± 1.6
D (mg/dL) 102.5± 1.8 275.8±∗10.0 301.9±∗4.8 306.9±∗10.1 318.5±∗16.3 319.6±∗11.8 321.5±∗9.3 322.2±∗9.7 335.7±∗16.7
B (mg/dL) 92.2± 3.1 306.3± 7.8 273.5±†22.7 272.2±†20.1 262.9±†18.5 261.5±†28.2 169.0±†29.1 200.3±†12.9 202.1±†6.4
C: control rats, D: diabetic rat, B: rosiglitazone with insulin combine-treated diabetic rats. Data are presented as mean± SEM. †P < 0.05 in B groups compared
with D; ∗P < 0.05 in D compared with C in the same group in the same week.
Table 2: Body weight levels in the study groups.
Weeks
Groups 0 1 2 3 4 5 6 7 8
C (gr) 100.0± 0.8 100.8± 0.8 101.1± 0.7 102.7± 0.7 107.6± 2.2 107.5± 0.8 109.3± 0.7 111.2± 0.8 112.6± 0.9
D (gr) 100.0± 1.8 91.5± 1.3 86.8∗ ± 1.3 75.5∗ ± 2.8 75.0∗ ± 1.7 73.5∗ ± 1.5 70.9∗ ± 1.5 71.6∗ ± 1.6 72.7∗ ± 1.8
B (gr) 100.0± 2.0 94.0± 2.1 89.1± 1.4 91.0† ± 1.2 95.3† ± 2.5 96.0† ± 2.4 97.0† ± 1.8 99† ± 2.3 100.0† ± 2.1
C: control rats, D: diabetic rat, B: rosiglitazone with insulin combine-treated diabetic rats. Data are presented as mean± SEM. †P < 0.05 in B groups compared
with D; ∗P < 0.05 in D compared with C in the same group in the same week.
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Figure 3: Effects of rosiglitazone with insulin combination therapy
on the MDA levels of rat left ventricular. C: control rats, D: diabetic
rat, group B: rosiglitazone with insulin combine-treated diabetic
rats. Data are presented as mean ± SEM. ∗#P < 0.05 in D group
compared with C and group B compared with D.
at 3-NT levels compared with the C and B groups (P <
0.0011). There were no statistically significant differences
between the B groups (Figure 4).
4. Discussion
In this study, we have demonstrated that group B prevents
glucose-induced oxidative stress in cardiac cells, an effect
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Figure 4: Effects of D + RSG + INS on the 3-nitrotyrosine/total
tyrosine levels of rat left ventricular. C: control rats, D: diabetic rat,
group B: rosiglitazone with insulin combine-treated diabetic rats.
∗P < 0.05 in D group compared with groups B and C.
independent from PPARγ, but distinctively dependent on
activated protein kinase (AMPK) activation. We also showed
that the ability of RSG to quench oxidative stress is conveyed
through the inhibition of NADPH oxidase. Furthermore, we
demonstrated that, downstream of AMPK activation, the
effect of RSG + INS on glucose-induced NADPH oxidase-
derived ROS production is mediated by the inhibition of the
diacylglycerol (DAG)-protein kinase C (PKC) pathway.
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In this study, we investigated the effect of RSG, a
member of the TZD family, on lipid profile and oxidative
status in STZ-induced diabetes mellitus rats. Many studies
have reported that TZDs act through PPARγ-dependent
mechanisms, and this is also true in endothelial cells. For
instance, RSG increased NO production in human umbilical
vein endothelial cells through a transcriptional mechanism
unrelated to eNOS expression but dependent on PPARγ
activation [16]. Interestingly, this effect has been attributed
to the inhibition of NO quenching by NADPH oxidase-
derived ROS [17].
Rosiglitazone is an agonist of the PPAR-γ, which is
found in insulin-dependent glucose-requiring tissues such as
adipose tissue, skeletal muscle, left ventricular muscle, and
liver tissue [18, 19]. The end result of PPAR-γ activation
is a reduction in hepatic glucose production and increased
insulin dependent glucose uptake in fat and skeletal tissues
[8, 19, 20].
Calkin et al. [21] observed that RSG had a significant
effect on HbA1c in diabetic mice. In addition, previous stud-
ies have reported that the administration of RSG induced a
significant decrease in serum glucose levels [18, 22]. In our
study, in group B-treated diabetic rats mean blood glucose
significantly decreased rapidly from 335 to 202.1 mg/dL
between weeks 0 and 8. The blood glucose levels started to
be reduced at 2th week of treatment compared to the level
of diabetic groups. Malinowski and Bolesta [23] found that
treatment of RSG responses began to be observed at 4th
week and were maximal at 12th week. With regard to this
report, RSG may indicate its full effect on blood glucose
at 12th week. In our previous studies, it was indicated that
the effects of treatment with RSG on the body weight of
diabetic rats was significant [18], but treatment of diabetic
rats with RSG (4 mg/kg/day) was caused a significant increase
compared with diabetic rats by the end of the treatment
period [24]. In our study, statistically significant increases
in body weight were observed group B-treated diabetic rats.
These weight changes may be function increased adipocyte
differentiation, which is one of the primary effects of group
B. The clinical significance of these modest weight changes
will require further evaluation in a long-term study.
We found a graded and significant elevation of glucose
levels from the initial phase through the sacrifice in D group
with and without RSG and we believe that it could be
secondary to the development of some degree of insulin
resistance although this was not evaluated in the present
study. The insulin-resistant state is commonly associated
with lipoprotein abnormalities such as hypertriglyceridemia,
high levels of VLDL, small dense LDL [25], and low levels
of HDL-cholesterol [26], which are risk factors for coronary
heart disease. The hypoglycemic and hypotriglyceridemic
action of TZDs is through the activation of PPAR-gama lead-
ing to increased insulin sensitivity of peripheral tissues and
lipoprotein lipase activity in the adipose tissue [27]. Zhao-
hui et al. [28] did not show a reduction of blood glucose
level in hypercholesterolemic rabbits receiving RSG for 6
weeks, as in the present study. Furthermore, we also observed
a significant elevation of triglycerides and HDL-C at the
time of euthanasia in RSG group. The effects of TZDs on
triglycerides have been somewhat more variable. Decreases
in triglyceride levels have been more frequently observed
with pioglitazone than with rosiglitazone. We cannot rule
out that these effects on glucose and triglycerides were due
to chance, as our evaluation period was short and the sample
was relatively. These findings are quite controversial in the
literature [28–30].
Boyle et al. [31] found that RSG reduced TAG, but
increased total cholesterol, LDL-C, and reduced HDL-C. In
contrast, pioglitazone reduced TAG, total cholesterol, and
LDL-C and increased HDL-C. Conversely, in their study,
Myerson et al. [32] observed reduced plasma fatty acid
concentrations and hepatic TAG content after RSG therapy.
Within that TZD group, marked differences have been
reported as regards the effect of different members on lipid
profiles in patients with type-2 diabetes. In the present study,
the administration of RSG + INS, a member of the TZD
family, decreased TC, TAG, and VLDL-C, LDL-C levels in
STZ diabetic rat.
Bagi et al. [33] reported that the reduced activity of
catalase may result in enhanced hydroxyl radical production
leading to enhanced lipid peroxidation in diabetes. Even
short-term activation of PPAR-γ by RSG reduces NAD(P)H
oxidase and enhances catalase activity causing a reduction
of superoxide and hydroxyl radical production, thereby
enhancing NO mediation of coronary vasodilation and
reducing lipid peroxidation in diabetes. These findings
suggest that activation of PPAR-gamma may exert an antiox-
idant activity by favorably altering the expression of specific
enzymes participating in the production and/or elimination
of reactive oxygen species.
Radi et al. [34] found that elevated levels of MDA were
brought down to the normal values by treatment with RSG.
In the present study, we have found that compared with
controls, in diabetic rats, the serum level of MDA (a marker
of in vivo lipid peroxidation) was significantly elevated,
which was reduced by group B treatment (Figure 3). On
the basis of study findings, we observed that even short-
term RSG treatment of rats with diabetes would, by reducing
oxidative stress. These results suggest that RSG + INS is
capable of reducing oxidative stress in rats with diabetes.
Patients with diabetes have modified levels of various mark-
ers of oxidative stress, indicating an overproduction of free
radicals, which have a key role in the development of diabetic
vascular complications [35]. When focusing on diabetic
vascular disease, it is the fine balance between the levels of
superoxide (O2
−), peroxynitrite (ONOO−), and NO, that
is, the key in determining the extent of vascular damage.
It is noteworthy that TZD show intracellular antioxidant
activity. This property may reflect “preventative” action since
these agents do not show direct antioxidant scavenging
activity on free radicals, but block several mechanisms that
in hyperglycaemic or hyperlipidaemic conditions lead to
the generation of oxidative stress. It has been observed
that PPAR-γ ligands inhibit the expression of inducible NO
synthase (iNOS) and, consequently, ONOO− production, in
mesangial cells and in cerebellar granule cells [36]. Similarly,
in mice with rheumatoid arthritis, pioglitazone and RSG
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have been shown to reduce the expression of iNOS and nitro-
tyrosine deposition [37].
It seems that this is the first study to investigate the effect
of group B on oxidative/nitrosative effect in left ventricular
of diabetes mellitus rats.
In summary, the present study demonstrates that in
diabetes, treatment with rosiglitazone with insulin combined
caused rapid reductions in oxidative stress that are not
associated with corrections of major metabolic derange-
ments. Our results clarify that mechanisms of TZD-induced
vascular protection include suppression of specific NADPH
oxidase subunit expression and ventricular muscle superox-
ide production similar to previously reported direct effects
of PPARγ ligands on vascular endothelial cells in vitro
[38]. The mechanisms of PPARγ-induced suppression of
NADPH oxidase subunits remain to be defined and con-
stitute an area of active investigation in our lab. We also
postulate that improvements in endothelial dysfunction
caused by sustained PPARγ activation in diabetes as well as
in other disorders associated with endothelial dysfunction
may be related to direct effects of PPARγ activation on
endothelial nitric oxide synthase activity [39] mediated by
TZD-induced alterations in post-translational mechanisms
regulating eNOS activity [40].
5. Conclusions
Ongoing studies in our laboratory will determine if direct
TZD-mediated activation of PPARγ coordinately regulates
the production of O2− and nitric oxide at the level of the
vascular wall to modulate the development of endothelial
dysfunction. These studies could further clarify the vascular
protective effects of PPARγ ligands and Thus, in diabetes-
related vascular diseases RSG treatment may be cardiopro-
tective.
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Yaman, “The effects of Escherichia coli-derived lipopolysac-
charides on plasma levels of malondialdehyde and 3-nitro-
tyrosine,” Clinical Chemistry and Laboratory Medicine, vol. 39,
pp. 491–493, 2001.
[16] D. S. Calnek, L. Mazzella, S. Roser, J. Roman, and C. M. Hart,
“Peroxisome proliferator-activated receptor γ ligands increase
release of nitric oxide from endothelial cells,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 52–57,
2003.
[17] J. Hwang, D. J. Kleinhenz, B. Lassègue, K. K. Griendling, S.
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